<DOC>
	<DOCNO>NCT00299000</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy two dose level Naglazyme infant age one year MPS VI monitor physical appearance , x-ray skeletal system growth .</brief_summary>
	<brief_title>A Phase 4 Two Dose Level Study Naglazyme ( TM ) ( Galsulfase ) Infants With MPS VI</brief_title>
	<detailed_description>The primary objective study evaluate efficacy two dose level Naglazyme prevent progression skeletal dysplasia infant age one year MPS VI monitor physical appearance , x-ray skeletal system growth . The secondary objective study evaluate efficacy two dose level Naglazyme prevent several measure disease progression infant age one year MPS VI monitor urinary GAGs , gross fine motor function , cardiac function , vision , hearing , use health resource . The safety objective study evaluate safety two dose level Naglazyme infant age one year MPS VI .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis VI</mesh_term>
	<criteria>Signed informed consent parent legal guardian Parent legal guardian willing able comply study procedure Equal great 36 week estimate gestational age physical exam birth Has diagnosis MPS VI base document prenatal diagnosis fibroblast leukocyte Nacetylgalactosamine 4sulfatase ( ASB ) enzyme activity level le 10 % low limit normal range measure laboratory Is less one year age Has evidence skeletal dysplasia base physical exam Parent legal guardian perceive unreliable unavailable study participation Use investigational drug within 30 day prior screen , requirement investigational agent prior completion schedule study assessment Has concurrent disease condition would interfere study participation safety ( i.e. , previously undergone hematopoietic stem cell transplantation bone marrow cord blood transplantation , major organ transplantation ) Any condition , view principle investigator , render subject high risk treatment compliance and/or complete study Has know hypersensitivity Naglazyme Has previously receive Naglazyme</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>